GSK, ovarian cancer and Jemperli
Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...
This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...
The price you pay for Jemperli may depend on factors such as your dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Jemperli.
GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback